Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1Locally Advanced Rectal Carcinoma 1Gliosarcoma 1Glioma 1Genetic Diseases, Inborn 1Esophageal Neoplasms 1Circulating Tumor DNA 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

pembrolizumab 2enfortumab vedotin 2Nivolumab 2Gemcitabine 2Cisplatin 2sacituzumab govitecan 1relatlimab 1erdafitinib 1avelumab 1Vinblastine 1Specimen Handling 1Paclitaxel 1Methotrexate 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Cystoscopy 1Circulating Tumor DNA 1Cell-Free Nucleic Acids 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Muscle Invasive Bladder Urothelial Carcinoma × Circulating Tumor DNA × Clear all
NCT05987241 2026-06-03

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI)

Phase 2/3 Recruiting
992 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡